CERo Therapeutics Holdings, Inc. (CERO)
Automate Your Wheel Strategy on CERO
With Tiblio's Option Bot, you can configure your own wheel strategy including CERO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CERO
- Rev/Share 0.0
- Book/Share -0.0961
- PB -92.0938
- Debt/Equity -4.1489
- CurrentRatio 0.7339
- ROIC -16.0013
- MktCap 4567414.0
- FreeCF/Share -1.5041
- PFCF -0.8859
- PE -2.183
- Debt/Assets 0.171
- DivYield 0
- ROE 6.6104
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CERO | D. Boral Capital | Hold | Buy | -- | $30 | June 23, 2025 |
News
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial's Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly.
Read More
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
Published: June 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 per share (the “Common Stock”).
Read More
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has issued additional shares of its Series D Preferred Stock to certain institutional investors (the “Investors”) pursuant to the securities purchase agreement previously entered into by and between the Company and such Investors on April 22, 2025 with respect to the issuance of shares of Series D Preferred Stock for an aggregate purchase price of up to $8 million, including …
Read More
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic (i.e.
Read More
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million (the “Equity Rule”)
Read More
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that TriStar Centennial Medical Center, through Sarah Cannon Research Institute (SCRI), in Nashville, Tennessee, is a clinical trial site for the Company's Phase 1 clinical of CER-1236. Collaborating with SCRI to advance cancer research, TriStar Centennial offers innovative clinical research trials for various disease indications. The trial is focused on patients with acute myeloid leukemia (AML), and patient enrollment is …
Read More
About CERo Therapeutics Holdings, Inc. (CERO)
- IPO Date 2021-11-30
- Website https://www.cero.bio
- Industry Biotechnology
- CEO Christopher B. Ehrlich
- Employees 8